Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akash Patnaik

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Molecular Cancer Therapeutics|August 29, 2020
Antihistamine Drug Ebastine Inhibits Cancer Growth by Targeting Polycomb Group Protein EZH2Qiaqia Li, Kilia Y Liu, Qipeng Liu, et al.
Cancer Discovery|May 29, 2014
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibitionEnrique González-Billalabeitia, Nina Seitzer, Su Jung Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2023
Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate CancerKiranj Chaudagar, Hanna M Hieromnimon, Rimpi Khurana, et al.
Nature Genetics|September 5, 2020
Author Correction: A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancerAndrea Lunardi, Ugo Ala, Mirjam T Epping, et al.
Nature Genetics|June 4, 2013
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancerAndrea Lunardi, Ugo Ala, Mirjam T Epping, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2024
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)Rahul Aggarwal, Glenn Heller, David W Hillman, et al.
JCO Precision Oncology|February 15, 2019
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials ConsortiumMaria I Carlo, Veda N Giri, Channing J Paller, et al.
Clinical Genitourinary Cancer|June 8, 2019
Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials ConsortiumChanning J Paller, Emmanuel S Antonarakis, Tomasz M Beer, et al.
Prostate Cancer and Prostatic Diseases|August 12, 2025
Correction: Natural killer cell infiltration in prostate cancers predict improved patient outcomesNicholas A Zorko, Allison Makovec, Andrew Elliott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2020
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a <i>BRCA1</i> or <i>BRCA2</i> Gene AlterationWassim Abida, Akash Patnaik, David Campbell, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Molecular Cancer Therapeutics|August 29, 2020
Antihistamine Drug Ebastine Inhibits Cancer Growth by Targeting Polycomb Group Protein EZH2Qiaqia Li, Kilia Y Liu, Qipeng Liu, et al.
Cancer Discovery|May 29, 2014
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibitionEnrique González-Billalabeitia, Nina Seitzer, Su Jung Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2023
Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate CancerKiranj Chaudagar, Hanna M Hieromnimon, Rimpi Khurana, et al.
Nature Genetics|September 5, 2020
Author Correction: A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancerAndrea Lunardi, Ugo Ala, Mirjam T Epping, et al.
Nature Genetics|June 4, 2013
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancerAndrea Lunardi, Ugo Ala, Mirjam T Epping, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2024
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)Rahul Aggarwal, Glenn Heller, David W Hillman, et al.
JCO Precision Oncology|February 15, 2019
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials ConsortiumMaria I Carlo, Veda N Giri, Channing J Paller, et al.
Clinical Genitourinary Cancer|June 8, 2019
Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials ConsortiumChanning J Paller, Emmanuel S Antonarakis, Tomasz M Beer, et al.
Prostate Cancer and Prostatic Diseases|August 12, 2025
Correction: Natural killer cell infiltration in prostate cancers predict improved patient outcomesNicholas A Zorko, Allison Makovec, Andrew Elliott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2020
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a <i>BRCA1</i> or <i>BRCA2</i> Gene AlterationWassim Abida, Akash Patnaik, David Campbell, et al.
Pageof 5